Payload Information

General Information of This Payload

Payload ID	PAY0ZJMHY
Name	Glucuronyl-monomethyl-auristatin E (MMAU)
Synonyms	Glucuronyl-monomethyl-auristatin E (MMAU) Click to Show/Hide
Target(s)	Microtubule (MT)	Target Info

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

EGFR-MMAU ADC [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.20% (Day 33)	Positive EGFR expression (EGFR+++/++)
Method Description	MMAU ADCs (3 mg/kg, intravenously four times at seven day intervals) induces efficient tumor cell killing in cell line-derived models of HSC-2 cells with EGFR expression with high expression.
In Vivo Model	HSC-2 CDX model
In Vitro Model	Oral cavity squamous cell carcinoma	HSC-2 cells		CVCL_1287
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 86.30% (Day 33)	Positive EGFR expression (EGFR+++/++)
Method Description	MMAU ADCs (10 mg/kg, intravenously four times at seven day intervals) induces efficient tumor cell killing in cell line-derived models of HSC-2 cells with EGFR expression with high expression.
In Vivo Model	HSC-2 CDX model
In Vitro Model	Oral cavity squamous cell carcinoma	HSC-2 cells		CVCL_1287

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25.00 pM	Low EGFR expression (EGFR+)
Method Description	Cells were seeded in a culture-treated 96-well clear plate and incubated at 37°C under 5% CO₂ for 24h. Serially diluted samples (50L) were added to each well and the plate was incubated at 37°C for 72h.
In Vitro Model	Non-small cell lung carcinoma	NCI-H522 cells		CVCL_1567
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30.00 pM	High EGFR expression (EGFR+++)
Method Description	Cells were seeded in a culture-treated 96-well clear plate and incubated at 37°C under 5% CO₂ for 24h. Serially diluted samples (50L) were added to each well and the plate was incubated at 37°C for 72h.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

References

Ref 1	Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility. Antibodies (Basel). 2018 Mar 22;7(2):15. doi: 10.3390/antib7020015.